Jan Marsal
1 – 10 of 42
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Alkaline sphingomyelinase (NPP7) impacts the homeostasis of intestinal T lymphocyte populations
(
- Contribution to journal › Article
- 2022
-
Mark
Response to : Response to: Irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls: Is it an overlooked comorbidity?' by Proft et al.
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Histological remission in inflammatory bowel disease and risk of adverse pregnancy outcomes : A nationwide study
(
- Contribution to journal › Article
-
Mark
Emergency subtotal colectomy rates in relation to anti-TNF therapy in inflammatory bowel disease patients : comparison of retrospective cohorts
2022) In Scandinavian Journal of Gastroenterology(
- Contribution to journal › Article
-
Mark
Gut dysbiosis associated with worse disease activity and physical function in axial spondyloarthritis
(
- Contribution to journal › Article
-
Mark
Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease
(
- Contribution to journal › Article
-
Mark
Editorial: intravenous to subcutaneous vedolizumab—switch without glitch! Authors' reply
2022) In Alimentary Pharmacology and Therapeutics(
- Contribution to journal › Debate/Note/Editorial
-
Mark
A novel food-based negative oral contrast agent compared with two conventional oral contrast agents in abdominal CT : a three-arm parallel blinded randomised controlled single-centre trial
(
- Contribution to journal › Article
-
Mark
Letter: to switch or not to switch, that is the question—author's reply
(
- Contribution to journal › Letter
- 2021
-
Mark
Real-world effectiveness of vedolizumab in inflammatory bowel disease : week 52 results from the Swedish prospective multicentre SVEAH study
(
- Contribution to journal › Article